Skip to main content

Drug Interactions between rimegepant and vimseltinib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

rimegepant vimseltinib

Applies to: rimegepant and vimseltinib

Consumer information for this interaction is not currently available.

ADJUST DOSING INTERVAL: Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of rimegepant. In vitro, rimegepant is a substrate of the P-gp and breast cancer resistance protein (BCRP) efflux membrane transporters. In a dedicated drug interaction study, concomitant administration of rimegepant oral disintegrating tablet with cyclosporine, a potent P-gp and BCRP inhibitor, increased rimegepant peak plasma concentration (Cmax) and systemic exposure (AUC) by 1.4- and 1.6-fold, respectively. Coadministration with quinidine, a potent P-gp inhibitor, increased rimegepant Cmax and AUC by 1.7- and 1.6-fold, respectively. Based on the similar magnitude of interaction, BCRP inhibition alone is not expected to have a clinically significant impact on rimegepant exposures.

MANAGEMENT: The manufacturer recommends avoiding another dose of rimegepant within 48 hours when coadministered with a potent P-gp inhibitor.

Drug and food interactions

Moderate

rimegepant food

Applies to: rimegepant

If you are receiving therapy with rimegepant you may want to avoid the regular consumption of large amounts of grapefruits and grapefruit juice. Grapefruit can raise the levels of rimegepant in your body and lead to increased side effects. If grapefruit or grapefruit juice is consumed along with rimegepant, the manufacturer recommends avoiding a second dose of rimegepant within 48 hours. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer